Abstract: The present invention relates to an ex vivo method for predicting anti-TNF alpha response in a patient with an inflammatory disease in which this treatment is generally indicated, comprising the steps of: a) Measuring, before any anti-TNF alpha treatment, the level LM of Burkholderiales in a patient stool sample, and b) Calculating the score S1=LM/Lref, Wherein: ?If S1>1, the patient is considered likely to have a clinical response to an anti-TNF alpha treatment, or; ?If S1?1, the patient is considered unlikely to have a clinical response to an anti-TNF alpha treatment, ?Lref being established on patients samples comprising a group (1) of patients with clinical improvement after treatment with TNF-alpha on the one hand, and a group (2) of patients who did not show any clinical improvement after treatment with TNF-alpha on the other hand, each of the groups (1) and (2) comprising at least 60 patients, by measuring the level of Burkholderiales at M0 in each of these groups, and determining the Lref value as

Abstract: Some embodiments are directed to a substance that inhibits P2Y12 receptor for use in the preventive treatment of systemic sclerosis in patients with Raynaud's phenomenon and a dysimmunity.